Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose long-acting octreotide first-line therapy for advanced G2-3 well-differentiated GEP-NETs
ChiCTR2600133789Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of octreotide in Gastroenteropancreatic Carcinoid Tumor, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
octreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on ChiCTR2600133789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133789.